RxDoctor Payments Data

Dawn Bodell, DO

Urology · Springfield, ORNPI 1306862206

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,482 of the $3,788 with a category attached, or 65.5%. 16 manufacturers reported payments, led by Axonics, Inc. at 54.9% of the total. Reporting peaked in 2024 at $2,295 and has fallen 87.8% since, to $281 in 2025.

$3,788in general payments, 2019–2025

Across 62 payments — averaging $61.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Medtronic$584
  • Coloplast$256
  • Olympus Corporation Of The Americas$191
  • Laborie Medical Technologies Corp.$186
  • Astellas Pharma US Inc$151
  • plus $339 from 10 others

What the payments were for

  • Travel & lodging$1,19231%
  • Food & beverage$2,48266%
  • Education$1143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,788 in reported general payments places this provider in the 70th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$103,022
Medicare patients
333
Services billed
3,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron59$31,812
MyrbetriqMirabegron34$24,693
Estradiol130$8,817
Trospium Chloride48$3,554
Methenamine Hippurate46$3,327
Trospium Chloride ErTrospium Chloride13$1,135
Tamsulosin Hcl62$853
Alfuzosin Hcl ErAlfuzosin Hcl14$666
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$577
Cephalexin33$397
Fluconazole19$295
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$278
Finasteride14$123
Oxycodone Hcl25$82
Levofloxacin14$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$151$24,69334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 153 urology providers in Oregon.

Other urology in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →